eli lilly glp-1 mounjaro endowment launches pill, kicking off showdown with Novo Nordisk Eli Lilly targets FDA approval

[PubMed Central ID: PMC4371177]

Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor

A person must also be at least 18 years old and meet one of the following criteria: Have a body mass index (BMI) of at least 35 at the time they begin the GLP-1 medication Have a BMI of at least 30 at the time of beginning the medication and at least one of the following diagnoses: Heart failure with preserved ejection fraction Uncontrolled hypertension Chronic kidney disease (stage 3a or above) Have a BMI of at least 27 at the time of beginning the medication and at least one of the following diagnoses: Pre-diabetes Previous heart attack Previous stroke Symptomatic peripheral artery disease Anyone who meets these qualifications but is eligible to receive GLP-1 coverage under Part D for another condition, like type 2 diabetes, wont qualify for the bridge program, CMS says

For patients who want to transition from a compounded product to an FDA-approved one, both clinicians cautioned that the process isnt always straightforward, as it may not be clear what dose a patient on a compounded product had been taking

Contact Your Insurance Provider: Reach out to Kaisers customer service to discuss the denial

10.1016/j.obpill.2024.100127 [DOI] [PMC free article] [PubMed] [Google Scholar] 3.Nauck MA, Meier JJ (2016) The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions